Clinical Trial

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Protocol Amendment History 6 changes
notable Trial sites expanded: 240 -> 251 locations 2026-08-15
notable Enrollment increased: 1250 -> 1750 participants 2026-07-24
notable Trial sites expanded: 233 -> 240 locations 2026-07-24
notable Trial sites expanded: 223 -> 233 locations 2026-06-13
notable Trial sites expanded: 207 -> 223 locations 2026-05-15
notable Trial sites expanded: 157 -> 207 locations 2026-04-18
Trial Details
NCT Number NCT07052903
Lead Sponsor Alnylam Pharmaceuticals
Conditions Transthyretin Amyloidosis With Cardiomyopathy
Enrollment 1,750 participants
Start Date 2025-07-02
Primary Completion 2030-05-28 (estimated)
Study Completion 2032-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14